brainberry new clinical study April 2024

New clinical study: Brainberry® improves cognitive performance

New clinical study: Short-term use of Brainberry® improves psychomotor speed and increases BDNF concentration

Maastricht, The Netherlands, 6th May 2024

Press release

New clinical data on the effect of Brainberry® for supporting cognitive function was published in the peer-reviewed European Journal of Nutrition. The results show a significant improvement in psychomotor speed and a significant increase in BDNF after just 1 week supplementation. This publication covers the second published clinical study with positive results from daily Brainberry® intake.

brainberry improves psychomotor speed and cognitive fundtion

Brainberry®: an active ingredient from Aronia supporting brain fitness.

Brainberry® is a clinically validated extract of Aronia melanocarpa, standardised for cyanidin galactoside. The extract is made from fresh berries of the Nero Eggert variety from the Baltics. Aronia melanocarpa is one of the richest natural sources of a powerful anthocyanin, cyanidin glycosides. These flavonoids are widely recognized for their antioxidant capacity and protective effects on vascular function. Brainberry® was the first aronia melanocarpa extract clinically tested in an earlier double-blind placebo controlled trial. In that first trial (1), Brainberry® intake resulted in significant improvement in focus and psycho-motor control and an increase in cognitive flexibility. The results of this study are also published in a peer reviewed journal (1).

The study: Shortterm Aronia melanocarpa extract supplementation improves cognitive performance: a randomized, doubleblind, placebocontrolled crossover study in healthy young adults

ACCESS THE FULL PUBLICATION

Introduction

This peer-reviewed study was published in the prestigious ”European Journal of Nutrition”, impact factor 5.0. Cognitive capacity is a key factor for learning, memorizing, and thinking. These skills usually peak in young adulthood. Typically, the regular consumption of fruits and specifically berries is often recommended to support these functions. The first clinical trial with Brainberry® was performed in mid-aged or elderly individuals. To fill in this gab, the aim of this research was to determine whether Aronia supplementation could improve the main cognitive domains such as memory and psychomotor speed in young individuals.

 

Methods

Thirty-five young adults took part in this randomized, double-blind, placebo-controlled cross-over study. They were provided with Brainberry® capsules daily for the duration of 1 (one) week. Cognitive performance was assessed via the Cambridge Neurophysiological Test Automated Battery (CANTAB) (2), the gold standard for precise and objective measures of specific cognitive processes. Additionally, mechanistic markers such as brain-derived neurotrophic factor (BDNF) were measured at baseline and after one week.

Results

All participants demonstrated excellent compliance with the protocol and tolerance of the product (Brainberry®). Psycho-motor control, defined as the time from release of the response button to selection of the target was significantly improved by 4.8% (figure 1).

brain berry improves cognitive function after 1 week

Figure 1. The difference in reaction time from baseline to 1 week after. *p<0.05 significant difference between groups; 4.5% decrease in the intervention group.

Moreover, serum BDNF concentrations were significantly higher with 5.7% in the intervention group after 1-week Brainberry® intake (p<0.05). BDNF is a protein responsible for neuronal survival and growth, essential for learning and memory (3) and highly relevant for the purpose of this research. Its increase showcases Brainberry®’s potential to support young adults in their daily activities such as learning and working.

Conclusion

This study demonstrates the great potential of Brainberry® in supporting brain fitness for all ages, more specifically psychomotor speed and cognitive performance in young adults. By adding Brainberry® to a nutritional supplement, consumers will benefit from a science-based support for brain functions and neuronal protection.

ACCESS THE FULL PUBLICATION

About Solabia Nutrition 

Solabia Nutrition, based in Maastricht, Netherlands is part of the Solabia Group and has developed a range of proprietary bioactive ingredients for the nutrition and healthcare industry. We focus on the development of innovative ingredients from plants and microalgae that address active living and healthy ageing. Our goal is to provide the nutrition and healthcare industry with science-based innovations that confer a real health benefit to consumers.

Feel free to contact via contact@solabia.com for more information on the possibilities Brainberry® has to offer. Further information can also be found on: https://solabianutrition.com and https://brainberry.eu


bonolive safe FDA GRAS

FDA GRAS Approval for Bonolive®

Bonolive® – Solabia-BioActor’s innovative women’s health ingredient, receives FDA GRAS approval

Maastricht, 6th March 2024

PRESS RELEASE

The United States Food and Drug Administration approves Bonolive® as safe for inclusion in supplements, beverages and functional foods. 

Bonolive safe foods supplements

Solabia-BioActor received а no objections letter from the U.S. Food and Drug Administration (FDA) regarding their Generally Recognized as Safe (GRAS) application for its women’s health ingredient Bonolive®. The FDA approves Bonolive® for inclusion in Dietary Supplements, Beverages and Functional Foods. 

For access to the FDA “no objection letter” please follow this link.

GRAS is a designation created by the FDA under the Federal Food, Drug and Cosmetic Act. It is a testament to the safety of a food ingredient or additive based on adequate evidence. Bonolive® had already shown a clean safety profile in published tox studies and a GRAS panel had concluded that Bonolive® should be considered GRAS.

Bonolive® is an oestrogen-free, patented ingredient, standardised for high levels of oleuropein. This all-natural ingredient is clinically validated in post-menopausal women to support women’s health during post-menopause. Human intervention studies showed that Bonolive® plays a key role in:

  • stimulating bone-building cells (osteoblasts) and stabilising bone mineral density
  • improving blood lipid profile
  • reducing joint pain and improving mobility.

A recent consumer study in menopausal women also showed that Bonolive® helps alleviating menopause related symptoms related to mood and skin appearance. Interestingly, a pharmacokinetics study showed that Bonolive® has an enhanced bioavailability in post-menopausal women.

Bonolive® targets women in peri- and post menopause that are looking for a safe, natural and oestrogen-free solution to the challenges of menopause. It is a true innovation as the only clinically evaluated olive leaf extract for women’s health. This ingredient is now also available in a convenient RTD format for everyday easy intake.

Feel free to contact us via info@bioactor.com for more information on the possibilities Bonolive® has to offer.

Further information can be found on: www.bonolive.com

 

About Solabia – BioActor

BioActor, a Solabia Nutrition company, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive formulations with clinical studies. The company focuses on the development of innovative bioactives that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

For further information, see www.bioactor.com


New Approved Health Claim for Watts'Up®

WATTS’UP® receives an additional approved health claim from Health Canada

Maastricht, 14th February 2024

PRESS RELEASE

Health Canada has issued a new Product Licence for WATTS’UP® and has approved the use of an additional health claim: “Helps to improve average power output during high intensity exercise in moderately trained individuals.

power strength wattsup bioactor solabia

WATTS’UP®, a customized flavonoid extract from sweet orange, has been tested in 2 double-blind placebo-controlled studies. The latest study was conducted in moderately trained men and women and showed a significant improvement in exercise performance with a significant increase in peak force and average 30 seconds power output.

Health Canada has issued a new Product Licence for WATTS’UP® with an enlarged scope. Pursuant to this Product Licence, WATTS’UP® is recommended to be used as “Athletic support” or “Workout/Exercise supplement.”

The following specific claims have been allowed by Health Canada: “Helps to improve average power output during high intensity exercise in moderately trained individuals” ; “Helps improve physical performance during exercise in trained male athletes”; and “Provides antioxidants that help cells to fight against the oxidative effect of free radicals and that helps protect cells and reduce oxidative damage and cell damage caused by free radicals”

The Journal of the International Scoiety of Sports Nutrition has published the results of the latest clinical study with WATTS’UP®. WATTS’UP® is a patent-protected citrus extract with enhanced bioavailability. It was tested in moderately trained athletes (both men and women) and showed a significant increase in power output during the Wingate anaerobic exercise test.

WATTS’UP® can be found on the market in multiple products in the USA, Europe, and Asia. It can be applied in various finished dosage forms, including powders, effervescent tablets, capsules, RTD sachets and beverages.

Feel free to contact us via info@bioactor.com for more information on the possibilities WATTS’UP® has to offer.

Further information can be found on: www.wattsup.eu

 

About Solabia – BioActor

BioActor, a Solabia Nutrition company, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive formulations with clinical studies. The company focuses on the development of innovative bioactives that address healthy living and ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

For further information, see www.bioactor.com


Solabia BioACtor Quadram Institute

BioActor & Quadram Institute announce collaboration

Solabia-BioActor announces the start of a collaboration with The Quadram Institute to assess the bioavailability and kinetics of Brainberry®

Maastricht/Norwich, 29th November  2023

Solabia-BioActor announces the start of a collaboration with The Quadram Institute to assess the bioavailability and kinetics of Brainberry®, Solabia-BioActor’s proprietary Aronia melanocarpa extract.

Solabia BioActor Quadram Institute

Solabia-BioActor has expertise and experience in developing innovative active ingredients, extracted from plants (botanicals) with great potential to support human health in terms of cognitive support, healthy aging and gut health enhancement.

 

The Quadram Institute is a premier research organization, based at the Norwich Research Park in the United Kingdom. It is home to researchers and clinicians that work together to develop world-class health, microbiome and food science. 

 

Solabia-BioActor’s Senior Scientist Sanne Ahles takes the lead on this collaboration together with Dr. Paul Kroon, a principal investigator at The Quadram Institute. Dr. Kroon is the leader of the Polyphenols and Health Group and his research focuses on understanding the mechanisms by which dietary polyphenols are absorbed and exert health benefits.

 

The objective of this project is to study the bioavailability and kinetics of Brainberry®, a proprietary aronia melanocarpa extract, in human volunteers. BioActor will carry-out the human intervention study and the Quadram Institute will identify and quantify a broad range of metabolites in a variety of samples obtained in the study.

Sanne Ahles, Senior Scientist at Solabia-BioActor comments:

“The bioavailability of Brainberry® has not been researched until this point. This collaboration with the Quadram Institute will allow us to broaden our knowledge regarding the anthocyanin metabolism and shed light on any possible differences between its steady-state bioavailability in young and older adults.”

About Solabia-BioActor

Solabia-BioActor, based in Maastricht, Netherlands, is a product development company that develops and supplies proprietary bioactive formulations to the health and sports nutrition industry. All Solabia-BioActor’s products are clinically tested, doping-free and from natural origin. The main focus areas are: gut microbiome, brain health, energy & vitality and skin health.


Brainberry®: Winner of Ingredient Idol 2023

Brainberry® is the Winner of Ingredient Idol 2023, Nootropics 

Maastricht, The Netherlands, 2nd November  2023

We are happy to announce that Brainberry® won the Ingredient Idol 2023 award in the Nootropics Category! The contest was organized by Informa Markets and held at SupplySide West on October 26, 2023 in Las Vegas.

Ingredient Idol winner

Out of all ingredients that were submitted for the competition in the Nootropics category, Brainberry® was selected as one of the three finalists that was invited to give a 3-min elevator pitch at the SupplySide West show in Las Vegas. Brainberry® was voted as Winner by the respected jury because of its unique clinically validated benefits on psychomotor control, better focus and mental flexibility.

Judges were three experienced professionals in the field of health and nutrition:

  • David Foreman, also known as “The Herbal Pharmacist” is an established author, and currently on the  editorial advisory board for Nutritional Outlook and on the content advisory board for Vitafoods Europe, Vitafoods Asia and Vitafoods Insights.

 

  • Douglas Lynch, CEO of MarketWell Nutrition Inc., has three decades of experience in the clinical nutrition and wellness industries. He has an award-winning product background in sales and marketing of dietary supplements, medical foods, functional foods, cosmetics, animal nutrition, and proprietary actives.

 

  • Diana Morgan, VP of global regulatory and government affairs for Nutrabolt, makers of the famous C4 Energy, is the founder of What’s Up with Supps. She has numerous years of experience in the natural products industry, having worked for reputable brands in the US nutritional supplement industry.

We are thankful to the jury and all visitors at SupplySide West for voting Brainberry® as the winner in the Nootropics category of Ingredient Idol 2023. Brainberry® was recognized for its advantages such as the low daily dose of 65mg, clinically backed benefits for improving focus and eye-hand coordination, and convenience of formulating in different product formats.

We strongly believe in the importance of clinical research backing up all our ingredients in order to offer true innovation in the health ingredients market. Brainberry® is an extract from Aronia Melanocarpa, standardized for Cyanadin-3-O-glycosides (>25%) and, specifically cyanidin-3-O-galactoside (>15%). It is able to cross the blood-brain barrier and improve neuronal signaling and synaptic plasticity. It is positioned for brain and cognitive support suitable for students, workers, gamers and athletes.

Consumer studies with acute and 7-days intake of 65mg Brainberry® among gamers and professional basketball players demonstrate improved eye-hand coordination, focus and reaction time, without negative impact on sleep or anxiety in self-reported questionnaires.

 

To learn more about Brainberry®, visit www.brainberry.eu, to explore other clinically validated ingredients by Solabia-BioActor, click here.


gut health or butyrate or short chain fatty acids

New clinical study: MicrobiomeX® improves microbiota composition and SCFA production

New clinical study: MicrobiomeX® improves microbiota composition and SCFA production

Maastricht, The Netherlands, 29th September  2023

Press release

New clinical and pre-clinical data from a study with MicrobiomeX® have been published in a peer-reviewed journal. It is a randomised, double-blind, placebo-controlled parallel study performed by scientists of Maastricht University, the department of Gastro-enterology of Maastricht University Medical Center and BioActor. It shows the potential of MicrobiomeX® to improve short-chain fatty acid (SCFA) profiles in the intestine. After 12 weeks of daily supplementation, there was a significant shift in the SCFA profile (p=0.022) towards butyrate. In addition, a reduction in faecal calprotectin levels was observed, a marker of gut inflammation. Interestingly, a new in-vitro study in the TIM2 model, where faecal samples from volunteers were tested, also showed a strong increase in butyrate production. These new clinical and pre-clinical results highlight MicrobiomeX®’s potential to support intestinal microbiota of subjects with features of metabolic syndrome.

gut health or butyrate or short chain fatty acids

MicrobiomeX®: an an active ingredient supporting the gut microbiome, developed by BioActor

MicrobiomeX® is a clinically validated blend of Citrus sinensis (sweet orange) and Citrus paradisi (grapefruit) extracts. These fruits are naturally rich in flavonoids, known for their anti-inflammatory and antiviral properties (1, 2). MicrobiomeX® already showed promising potential to reduce markers of gut inflammation and increase SCFAs in previous in-vitro and ex-vivo studies conducted with this ingredient (3, 4). Supplement brands all over the world have adopted MicrobiomeX® in their formulations, typically positioned for improving gut microbiome balance and immune system regulation.

The study: Citrus Extract High in Flavonoids Beneficially Alters Intestinal Metabolic Responses in Subjects with Features of Metabolic Syndrome

 

Introduction

This study (5) was published in the international journal “Foods”. The western diet and lifestyle may be the leading causes for the development of various metabolic disorders. An overlooked factor is the gut microbiota composition, which should be considered as a factor determining health status. A healthy gut is related to mental wellbeing and strong immunity. This study aimed to evaluate the benefits of MicrobiomeX® supplementation on the intestinal microbiome of subjects with metabolic disorder traits.

Methods

Fifty adult subjects with features of metabolic syndrome took part in the study. They ingested 500mg MicrobiomeX® or placebo daily for 12 weeks. Additionally, seven volunteers provided faecal samples that were introduced into a TIM-2 system for further analysis. The TIM-2 is a computer-controlled model in an anaerobic environment that replicates the appropriate conditions for microbial growth in the human colon and is able to measure microbiota composition and SCFA production.

Results

A significant shift in the SCFA profile towards more butyrate (p=0.022) was observed in the MicrobiomeX® group after the 12-week supplementation period. An increase in SCFA production was also found in the TIM-2 model, that was mainly due to an increased production of butyrate, acetate and valerate. Additionally, in the MicrobiomeX® group, a trend in calprotectin reduction was observed, which is a marker of gut inflammation. Both in vivo and in vitro data confirm the benefits of MicrobiomeX on gut health, specifically the increased butyrate production and improved SCFA profile. These findings are in line with previous in vitro results and show that MicrobiomeX® can beneficially modulate the gut microbiome.

Conclusion

This study demonstrates the great potential of MicrobiomeX® in playing a role in gut health modulation. This is indicated by the significant increase in SCFAs, mainly butyrate, and a reduction in calprotectin, as found in the present study. By adding MicrobiomeX® to your supplement, you can offer customers a science-based support for gut health. It is an alternative to common prebiotics and an ideal partner for synbiotic formulation targeting gut health and immunity.

Click here to read the complete publication

About BioActor

BioActor, based in Maastricht, Netherlands is part of the Solabia Group and has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. We focus on the development of innovative activities that address active living and healthy ageing. Our goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact via info@bioactor.com for more information on the possibilities MicrobiomeXl® has to offer. Further information can also be found on: https://solabianutrition.com/products/microbiomex/ and https://microbiomex.com/


Actiful: a sweet orange and pomegranate extract suitable for supplements

New publication of clinical data: Actiful® reduces Methylglyoxal, an important marker for healthy aging

New publication of clinical data: Actiful® reduces Methylglyoxal, an important marker for healthy ageing

Maastricht, The Netherlands, 15th September  2023

Press release

A randomized double blinded crossover study performed by Maastricht University, showed the potential of Actiful® as a dietary modulator against advanced glycation end-products (AGEs). AGEs are associated with various age-related chronic diseases. After a 4-week period of Actiful® consumption in healthy elderly subjects, plasma levels of methylglyoxal (MGO) decreased significantly by 9.8% (p = 0.042). These new clinical results highlight Actiful®’s potential to mitigate age-related diseases like diabetes, vascular dysfunction and neurodegeneration. 

Actiful: a sweet orange and pomegranate extract suitable for supplements

Actiful®: an energy-boosting ingredient developed by BioActor

Actiful® is a clinically validated blend of Citrus sinensis (sweet orange) and Punica granatum (pomegranate) extracts. These plants are abundant in bioactive polyphenolic components, mainly flavonoids (1, 2) . Actiful® has a dual mode of action: by increasing synthesis of nitric oxide and by improving ATP production through an increased mitochondrial respiration efficiency (3). In the first clinical study, Actiful® demonstrated to improve energy, mood and antioxidant status in healthy elderly individuals. Actiful® is used globally by leading supplement brands in a vast array of products supporting an active lifestyle and healthy aging.

The study: A Citrus and Pomegranate Complex Reduces Methylglyoxal in Healthy Elderly Subjects: Secondary Analysis of a Double-Blind Randomized Cross-Over Clinical Trial

 

Introduction

This study (4) was published in the International Jouranl of Molecular Sciences . It focuses on the evaluation of additional biomarkers and the effect of Actiful® in reducing the concentrations of reactive α-dicarbonyl compounds (specifically methylglyoxal, glyoxal, and 3-deoxyglucosone) in the blood of healthy elderly participants. These α-dicarbonyls are known to contribute to the formation of advanced glycation end-products (AGEs), which are associated with various chronic diseases, including diabetes and cardiovascular diseases (5).

Methods

Thirty-six healthy elderly subjects were recruited for this double-blind, randomized crossover clinical trial. They received either 700 mg of Actiful® in capsules, or a placebo for four weeks, with a 4-week washout period in between.

Blood samples were collected during the test day to measure α-Dicarbonyls in plasma. This was achieved via ultra-performance liquid chromatography tandem mass spectrometry.

Results

A significant reduction in plasma methylglyoxal concentrations was observed during a 4-week supplementation period. This reduction suggests a potential benefit in terms of reducing the formation of harmful AGEs, which could be attributed to the antioxidant properties of the active compounds in the supplement. The observed reduction in methylglyoxal was around 9.8%, which could be of clinical relevance in preventing or managing age-related conditions related to AGEs formation, like cardiovascular related diseases, diabetes and neurodegeneration. This confirms the importance of exploring promising nutraceuticals like Actiful® as potential healthy ageing strategies to mitigate the impact of reactive α-dicarbonyl compounds on health.

Conclusion

This study demonstrates the great potential of Actiful® for playing a role in healthy ageing. This is indicated by the significant reduction in AGEs, specifically MGO, found in the present study.

Click here to read the complete publication

About BioActor

BioActor, based in Maastricht, Netherlands is part of the Solabia Group and has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. We focus on the development of innovative activities that address active living and healthy ageing. Our goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact via info@bioactor.com for more information on the possibilities Actiful® has to offer. Further information can also be found on: https://actiful.eu and https://solabianutrition.com/products/actiful


BIOACTOR and PIXIENCE start collaboration on validation of skin imaging technology in nutrition studies

BIOACTOR and PIXIENCE start collaboration on validation of skin imaging technology in nutrition studies

BIOACTOR and PIXIENCE start collaboration on validation of skin imaging technology in nutrition studies

MAASTRICHT/TOULOUSE, August 22nd, 2023

Press release
BIOACTOR and PIXIENCE announce the start of a collaboration to test and validate an innovative skin imaging and testing technology in the context of a clinical study with a nutritional bioactive.

BIOACTOR and PIXIENCE start collaboration on validation of skin imaging technology in nutrition studies

BIOACTOR and PIXIENCE announce the start of a collaboration to test and validate an innovative skin imaging and testing technology in the context of a clinical study with a nutritional bioactive.

PIXIENCE has developed an innovative skin image capturing device (C-Cube) and image analysis software (QuickScale) for the evaluation of several skin parameters, including the evaluation of 3D images.

BIOACTOR has expertise in the clinical validation of health effects of natural compounds and is now setting-up a clinical testing platform around nutritional actives for skin health.

PIXIENCE is developing the C-Cube Clinical Edition and BIOACTOR will carry-out beta testing of the Clinical Edition in a new clinical study on an oral nutritional product. PIXIENCE will provide technical assistance to BIOACTOR for the skin image analysis in this new clinical study.

Sebastien Mangeruca, CEO of PIXIENCE comments:
We have initially developed our C-Cube and QuickScale suite of technologies for the evaluation of topical cosmetic products. BIOACTOR’s experience in running clinical studies for nutrition and its active programme around nutrition and skin health, makes them an ideal partner for testing and validating of our C-Cube Clinical Edition for nutrition studies”.

Hans van der Saag, CEO of BIOACTOR comments:
BIOACTOR is delighted to work with PIXIENCE, as PIXIENCE has developed a best in class skin imaging and analysis technology that will allow us to further improve our skin health for nutrition platform. BIOACTOR wants to bring clinically backed innovation to the nutrition industry. BIOACTOR tests all of its products in scientifically robust human intervention studies, working with partners like PIXIENCE and the Department of Health and Nutrition of Maastricht University.

About BIOACTOR

BIOACTOR, based in Maastricht, Netherlands, is a product development company that develops and supplies proprietary bioactive formulations to the health and sports nutrition industry. All BIOACTOR’s products are clinically tested, doping-free and from natural origin. The main focus areas are: gut microbiome, brain health, energy & vitality and skin health.

For more information, please contact:

BioActor
Hans van der Saag, CEO
Email: hans.vandersaag@bioactor.com

Pixience
Sébastien Mangeruca, CEO
Email: Sebastien.mangeruca@pixience.com
www.pixience.com


New publication Naxus® consumption supports weight management through reduction of actual calorie intake in an ad libitum meal

New publication: Naxus® consumption supports weight management through reduction of actual calorie intake in an ad libitum meal

New publication: Naxus® consumption supports weight management through reduction of actual calorie intake in an ad libitum meal

Maastricht, The Netherlands, 27th July 2023

Press release
This randomized controlled crossover study showed Naxus®’ potential for appetite control and weight management. In a 21-day trial with healthy adult males, it was reported that consumption of a blend of Naxus® and inulin showed significantly lower calorie intake in an ad libitum meal (838 kcal vs. 1023 kcal) while reporting no changes in appetite. The blend was also shown to increase faecal SCFA concentrations. These results highlight Naxus®’s potential to transform appetite regulation.

New publication Naxus® consumption supports weight management through reduction of actual calorie intake in an ad libitum meal

Naxus®: clinically validated and developed by BioActor

Naxus® is a clinically validated arabinoxylan extract developed by BioActor, derived from wheat endosperm. It has been extensively studied and shown to have beneficial effects on microbiota composition, glycaemic control, and immune system function.

Naxus® promotes the growth of beneficial bacteria, production of Short Chain Fatty Acids (SCFA) and improves glycaemic control by inducing GPR43 signaling which leads to reduced glucose peaks and improved insulin sensitivity (1, 2). It also strengthens the immune system through various mechanisms (3, 4, 5). It is a well-researched ingredient with significant potential for enhancing overall health and well-being.

The study: Chronic consumption of a blend of inulin and Naxus® reduces energy intake in an ad libitum meal but does not influence perceptions of appetite and satiety

Introduction

Two dominant bacterial strains account for more than 90% of the total bacterial gut community: Bacteroidetes and Firmicutes (6). They are widely believed to have important effects on the maintenance of normal intestinal homeostasis. Stressors associated with modern lifestyles (e.g. low fibre diet) can chronically change the bacterial gut composition and lead to the increase of more virulent microbes that adversely affect the health of the host.

Gut microbiota break down fibre from our diet and produce SCFAs such as propionate, acetate, and butyrate as a result. These metabolites lead to activation of a pathway that is linked to appetite reduction.

Specifically, propionate and acetate bind to a receptor called GPR43, which is found in cells lining our stomach and intestines (7). Activation of GPR43 leads to a cascade of signals eventually triggering the production of GLP-1 and PYY, two hormones involved in inducing satiety.

Naxus has previously been shown to increase propionate levels and GLP-1 production (8). In this current study, it was investigated whether a blend of Naxus® and inulin would positively affect satiety and energy intake.

Methods

In this cross-over study, the authors investigated the effect of inulin + Naxus® on 20 healthy adult males aged between 22 and 55 with no evidence of metabolic or cardiovascular disease.

Each participant took part in both control and intervention conditions, each lasting 21 days. Both the treatment and control groups had to drink two sachets of dry powder dissolved in 150 ml of water daily for 21 days. Therefore, the participants consumed the intervention (or the control) sachet for 21 days following a 14-day period washout, and afterwards the control (or the intervention) sachet for an additional 21 days. The intervention sachet contained 2 g of Naxus® and 2 g inulin, whereas the control sachet contained 4 g of maltodextrin.

After a 14-day wash-out period, participants switched to the other drink for another 21 days. The study comprised 4 visits to assess the participants’ perceived satiety and appetite, the energy intake in an ad libitum meal, faecal SCFA concentration, and the faecal microbiota composition.

Results

Appetite control and calorie intake

The study found that the mean energy intake in an ad libitum meal were significantly lower during the treatment period (838 kcal) compared to the control period (1023 kcal) (p<0.05).

Surprisingly, no changes in self-reported appetite were found. This difference between self-reported appetite and actual calorie intake is common in studies involving prebiotics, which is why measuring actual food intake provides a more objective measure.

Naxus and Inulin results on kcal intake

Microbial composition

Significant changes in the microbial composition of fecal samples were noted, showing noteworthy increases in the abundance of Bifidobacteria (p = 0.035), Lactobacilli (p = 0.061), and Propionibacteria (p = 0.02).

Short-chain fatty acids

Moreover, these changes were accompanied by an elevation in the concentration of short-chain fatty acids (SCFAs), which are known to be associated with gut health. More specifically, an increase of acetate in the faeces sample was reported after 21 days (p=0.02). Acetate has the ability to independently influence appetite, which may explain why the participants consumed fewer calories during a single meal.

The hypothesized increase in propionate levels in the faeces sample was only minimal and not statistically significant (p=0.07). However, it is important to note that faecal propionate concentration alone does not reflect the absorption by the body. Additionally, the signals of propionate in the liver and bloodstream, which were not measured in this study, could potentially have a more significant impact on appetite regulation.

Triple effect

Overall, the results show that the chronic consumption of a blend of inulin and Naxus® leads to a reduction in energy intake, an increase in faecal SCFA concentrations, and an increase in beneficial gut bacteria.

Conclusion

This research indicates that a combination of inulin and Naxus® has positive effects on gut health and confirms existing data that Naxus® positively influences appetite control.

This publication also emphasizes the importance of new studies focusing on the effect of Naxus® on enhancing and tailoring nutritional products to promote satiety and help weight management.

Click here to read the complete publication

About BioActor

BioActor, based in Maastricht, Netherlands is part of the Solabia Group and has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. We focus on the development of innovative activities that address active living and healthy ageing. Our goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact via info@bioactor.com for more information on the possibilities Naxus® has to offer. Further information can also be found on: www.naxus.nl or www.bioactor.com/products/naxus.


The importance of clinical research: An interview with BioActor's in-house scientists

The importance of clinical research: An interview with BioActor’s in-house scientists

Maastricht, The Netherlands, 29th June 2023

Interview
In the world of clinical research and scientific exploration, BioActor stands out as a leading company dedicated to the development of health ingredients. At the forefront of BioActor’s research and development (R&D) efforts are Sanne Ahles and Maria Imperatrice, two certified clinical research scientists who play vital roles in the BioActor’s R&D initiatives. In this interview, Sanne and Maria provide insights into their responsibilities, experiences, and the challenges they face in their pursuit of scientific advancement.

Could you introduce yourself and your role within BioActor?

Sanne: My name is Sanne Ahles and I am a clinical research scientist at BioActor. In addition, I am a PhD candidate at the Department of Nutrition and Movement Sciences at Maastricht University. I obtained my master’s degree in biomedical sciences after my internship at BioActor, after which I started working as a researcher.

Within BioActor, I am responsible for the research regarding our product Brainberry®, mainly focused on cognitive performance and vascular function. Over the years, I have designed, performed, analyzed, and reported various clinical studies, as well as written a systematic literature review.

Maria: My name is Maria Imperatrice and I also work as a clinical research scientist at BioActor. My research focus is Healthy Ageing and I’m currently performing two studies, Actiful2 and FEMMED, on two of our ingredients (Actiful® and Bonolive®) to evaluate their effect on exercise performance and postmenopausal symptoms, respectively.

I obtained my Bachelor Degree in Biology and my Master in Human Nutrition at the University “Federico II Di Napoli” in Italy, and my second master’s degree in Human Movement Sciences, with a specialisation in Sport and Nutrition, at Maastricht University.

At BioActor, we highly value clinical research because it plays a crucial role in providing evidence-based ingredients. What does clinical research entail and what do you like about it?

Sanne: Clinical research entails many different processes. This includes idea formation and initial literature searches, finding collaborations, obtaining ethics approval, practical work, data analyses, writing reports and papers, and communicating our results at national and international conferences.

Maria: A very interesting part for us is the ideation of the study. At BioActor we highly value innovation, which is why before starting a new clinical trial, we sit in brainstorming sessions with the R&D, marketing and sales teams to try to find white spaces in the current knowledge that can be of interest for the common public and different health domains. Once we find an interesting and never explored topic, the investigation can start.

Could you briefly take us through the process of a clinical trial?

Sanne: First, we initiate the idea formation process by brainstorming ideas that are relevant to customer questions or explore new areas of interest. Next, we perform literature searches to look for relevant papers, available data, and discover white space; topics that have not yet been researched.

Then we reach out to a collaborator, usually a professor at a University, to work with on developing a protocol for ethics review.

Maria: Once we obtain ethics approval, we dive into the practical phase of the clinical trial. This involves engaging with participants through visits where we collect data. This includes not only traditional data that we can extrapolate by collecting blood samples, but also performing tests to evaluate outcomes like reaction time, exercise capacity and mental flexibility.

It’s an interactive and rewarding experience that brings our research to life and allows us to better understand how our ingredients contribute to improving human health and develop evidence-based solutions. Afterwards, we analyze the data, draw conclusions, and share our findings through peer-reviewed publications. It’s a cool journey from start to finish!

Which of the above do you enjoy the most as a scientist?

Sanne: I enjoy collaborating with other companies or academic institutes! It’s such an incredible opportunity for us to broaden our knowledge and take our research to the next level. The energy and creativity that come from working with diverse teams is truly great.

Maria: The practical side of our work is always interesting! Collecting data means we get to perform visits with participants, and trust me, it’s never boring when you’re involved in a human study. The hands-on experience and the constant interaction with people make it such an exciting and fulfilling part of our job.

What is the biggest challenge in designing a study?

Sanne: In my opinion, the biggest challenge in designing a study is obtaining ethics approval, which is a rigorous and time-consuming process. We meticulously prepare documents explaining our research goals, methodology, and participant recruitment.

The ethical committee thoroughly reviews these documents, granting final approval for each aspect of our research.

Maria: I agree! Obtaining ethics approval is a significant challenge. However, this process is crucial for upholding ethical standards and protecting participant rights.

It also adds credibility to our research, fostering trust and allowing our findings to have a greater impact. Despite the challenges, navigating the ethics approval process is vital for conducting valuable and ethically sound research.

What is the best part of working at BioActor as a scientist?

Sanne & Maria: Being a scientist at BioActor is truly rewarding due to the chance to collaborate with a dynamic and passionate team of international colleagues. Within BioActor, we also see other aspects of the company besides R&D.

Our weekly company meetings allow us to really understand the bigger picture of the company and understand what each department entails. Consequently, we explore different facets of the company and gain valuable insights beyond our specific research and development focus.

BioActor: Using clinical science as the key to innovative ingredients

Sanne Ahles and Maria Imperatrice exemplify the passion and dedication that drive BioActor’s pursuit of finding new health effects of ingredients and advancing scientific innovation. From ideation to practical implementation, data analysis, and knowledge dissemination; they are pushing the boundaries of scientific knowledge and embracing the multidisciplinary nature of their work. Sanne and Maria contribute to BioActor’s mission of creating innovative and impactful solutions for a healthier life.